NASDAQ:CNSP CNS Pharmaceuticals Q3 2026 Earnings Results & Report $3.28 +0.39 (+13.49%) As of 02:07 PM Eastern This is a fair market value price provided by Massive. Learn more. CNS Pharmaceuticals beat analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.24 versus the -$0.27 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 16, 2026TimeBefore Market OpensConference Call7:00 AM ET CNS Pharmaceuticals EPS ResultsActual EPS-$0.24Consensus EPS -$0.27Beat/MissBeat by +$0.03One Year Ago EPSN/AEPS Beat Rate4 of last 6 quartersCNS Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CNS Pharmaceuticals Q3 2026 Earnings FAQ Did CNS Pharmaceuticals beat earnings estimates for Q3 2026? CNS Pharmaceuticals (NASDAQ:CNSP) reported earnings of -$0.24 per share for Q3 2026, beating the consensus estimate of -$0.27. The report was announced on Monday, November 16, 2026. CNS Pharmaceuticals Earnings HeadlinesCNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic PipelineNovember 16 at 8:45 AM | finance.yahoo.comCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic TransformationAugust 12, 2026 | finanznachrichten.deWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 16 at 1:00 AM | Base Camp Trading (Ad)CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Oversubscribed $22.5M Financing, Growth Strategy in Investor PresentationJune 9, 2026 | markets.businessinsider.comCNS Pharmaceuticals (NASDAQ: CNSP) Reports First-Quarter 2026 Results, Advances Strategic TransformationMay 15, 2026 | theglobeandmail.comForget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6May 14, 2026 | 247wallst.comSee More CNS Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CNS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CNS Pharmaceuticals and other key companies, straight to your email. Email Address About CNS PharmaceuticalsCNS Pharmaceuticals (NASDAQ:CNSP) is a biopharmaceutical company focused on developing treatments for cancers of the brain and central nervous system. Its research has centered on investigational therapies intended to address the challenges of treating tumors that affect these areas. The company’s lead candidate has been berubicin, an experimental anthracycline designed to cross the blood-brain barrier. CNS Pharmaceuticals has evaluated berubicin for glioblastoma, an aggressive form of brain cancer. The drug remains investigational and is not an approved treatment. The company has also pursued other experimental compounds for brain and central nervous system conditions. Its work has included clinical development and research; it does not market an established portfolio of approved medicines.View CNS Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.